Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$8.22
$8.17
$4.02
$9.15
$376.37M2.82692,487 shsN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.70
-1.7%
$1.71
$1.40
$7.88
$76.79M1.59339,218 shs39,329 shs
Genprex stock logo
GNPX
Genprex
$0.23
+2.2%
$0.28
$0.20
$3.97
$6.20M-0.414.14 million shs1.40 million shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.78
+6.5%
$36.61
$1.72
$54.30
$205.47M1360,428 shs54,162 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.67
-2.4%
$0.87
$0.66
$2.29
$26.98M1.66161,667 shs198,826 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-1.73%-1.16%+1.19%+8.97%-67.68%
Genprex stock logo
GNPX
Genprex
+3.59%-0.48%-35.80%-0.96%-87.91%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
+6.49%+12.41%+11.57%+7.03%+880.14%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-2.39%-7.56%-21.53%-28.40%-66.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.9691 of 5 stars
2.02.00.00.03.32.51.3
Genprex stock logo
GNPX
Genprex
1.6388 of 5 stars
0.04.00.04.72.10.00.6
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3.0039 of 5 stars
3.45.00.00.02.12.50.0
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.9199 of 5 stars
0.03.00.00.03.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00
N/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0017.65% Upside
Genprex stock logo
GNPX
Genprex
0.00
N/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.80
Moderate Buy$56.5057.91% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SCYX, MNPR, GNPX, EPIX, and ADMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
4/2/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/1/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$74.46M5.05N/AN/A($0.47) per share-17.49
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
Genprex stock logo
GNPX
Genprex
N/AN/AN/AN/A$0.15 per shareN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.75M7.02N/AN/A$1.45 per share0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)
Genprex stock logo
GNPX
Genprex
-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A13.50N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)

Latest SCYX, MNPR, GNPX, EPIX, and ADMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
5/12/2025Q1 2025
Genprex stock logo
GNPX
Genprex
-$0.82-$0.26+$0.56-$0.26N/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Genprex stock logo
GNPX
Genprex
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
21.25
4.53
4.17
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15
Genprex stock logo
GNPX
Genprex
N/A
1.94
1.94
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83

Institutional Ownership

CompanyInstitutional Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
69.97%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Genprex stock logo
GNPX
Genprex
14.05%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
18.90%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Genprex stock logo
GNPX
Genprex
8.47%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
13845.79 million37.13 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Genprex stock logo
GNPX
Genprex
2027.82 million25.47 millionNo Data
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable

Recent News About These Companies

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamas Pharmaceuticals stock logo

Adamas Pharmaceuticals NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.70 -0.03 (-1.73%)
As of 06/30/2025 04:00 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Genprex stock logo

Genprex NASDAQ:GNPX

$0.23 +0.00 (+2.20%)
As of 06/30/2025 04:00 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.78 +2.18 (+6.49%)
As of 06/30/2025 04:00 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.67 -0.02 (-2.39%)
As of 06/30/2025 04:00 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.